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Summary.-Both misonidazole (MISO) and hyperthermia are known to enhance the
radiation response of hypoxic cells, and to be selectively cytotoxic against cells in a
hypoxic and acidic environment. The ability of these conditions to modify the effect
of irradiation and their individual relationship was studied in a C3H mammary
carcinoma and its surrounding skin.
Simultaneous treatment with MISO, hyperthermia and radiation increased the
radiation effect, with enhancement ratios (ER) of up to about 15 (1 mg/g MISO and
43*50C for 60 min.). However, such treatment also caused a smaller hyperthermic
radiosensitizationofthenormaltissue, sothatthetherapeutic ratiowasonlyincreased
by a factor of about 3 compared to radiation alone.
Simultaneous MISO and radiation followed by hyperthermia 4 h later gave a
moderate enhancement, with ER up to 3 in the tumour, but with no enhancement of
the normal tissue, so that there is a similar 3-fold increase in therapeutic gain.
The mechanismbywhich MISO and hyperthermia enhanced the radiation response
may be explained as an independent action of the hypoxic radiosensitization of MISO
and the selective hyperthermic cytotoxicity against acidic and chronic hypoxic cells;
simultaneous hyperthermia added a further heat-induced general radiosensitization.
Surprisingly, no MISO cytotoxicity could be detected in this tumour system, with or
without simultaneous hyperthermia.
The results indicate that in the propertreatment schedule, MISO maybe avaluable
addition to a combined hyperthermia and radiation treatment.
MISONIDAZOLE(MISO)andhyperthermia
have a number of common features which
make them potentially valuable in com-
bined treatment with radiation for local
tumour control.
Hyperthermia has been shown to sensi-
tize to the effect of radiation. This occurs
by several mechanisms including: direct
increased cellular radiosensitivity, de-
creased accumulation ofsublethal damage,
and sensitization of cells in radioresistant
phases of the cell cycle (Bronk, 1976;
Dewey et at., 1977). Furthermore, heat
may sensitize hypoxic cells more than well
oxygenated cells, thus causing a decreased
oxygen enhancement ratio (Robinson et
al., 1974a,b;Kimetal., 1975). However, the
data on this special effect on hypoxic cells
are ambiguous (Power & Harris, 1977;
Myers & Field, 1979). The heat-induced
radiosensitization is strongly dependent
on the time of application of the two
modalities. In general, optimal sensitiza-
tion is obtained by simultaneous treat-
ment, any interval between the two com-
ponents tending to reduce the sensitiza-
tion effect (Stewart & Denekamp, 1978;
Overgaard, 1979b). If hyperthermia is
given more than 4 h after radiation, the
direct radiosensitizing effect is lost. When
studied in normal tissues and tumours in
vivo, the radiosensitizing effect of hyper-
thermia is approximately similar, and it is
doubtful whether a simultaneous treat-RADIATION, MISONIDAZOLE AND HYPERTHERMIA IN VIVO
ment would improve the therapeutic ratio
(Gillette & Ensley, 1979; Overgaard,
1979b).
Besides its ability to act as a radio-
sensitizer, heat also has a direct cytotoxic
effect, and may control experimental
tumours with an acceptable degree of
normal-tissue damage (Overgaard & Over-
gaard, 1972; Overgaard, 1978; Overgaard
& Suit, 1979). This cytotoxicity is strongly
enhanced by certain environment factors,
and moderate hyperthermia is able to
destroy almost selectively cells in areas of
chronic hypoxia, acidity and insufficient
nutrition (typical of large areas of solid
tumours) (Overgaard, 1976, 1978; Ger-
weck et al., 1979). The fact that cells in
such an environment are also the most
radioresistant may indirectly influence the
response to combined heat-radiation treat-
ment, since a smaller radiation dose may
be adequate to control the remaining
better-oxygenated peripheral tumour cells.
In contrast to the hyperthermic radio-
sensitization, this cytotoxic effect shows
no time relation to the radiation treat-
ment (Overgaard, 1978, 1979b).
Misonidazole was originally introduced
as a drug which sensitizes hypoxic cells
for radiation (Fowler et al., 1976; Dene-
kamp & Fowler, 1978). This sensitization
occurs only inhypoxic cells, and there is no
influence on the radiation response of
cells situated in a well oxygenated environ-
ment such as in most normal tissues.
More recent studies have furthermore
shown that under hypoxia MISO may also
exhibit a direct cytotoxic effect (Hall &
Roizin-Towle, 1975; Fowler et al., 1976;
Brown, 1977; Foster, 1978). This effect
resembles that of hyperthermia in that
increased acidity also increases the cyto-
toxicity of MISO against hypoxic cells
(Stratford, 1977). Both the radiosensitiza-
tion of hypoxic cells and the cytotoxicity
are dose-dependent; the radiosensitization
generally occurs at lower doses than those
causing measurable cytotoxicity effects in
experimental solid tumours (Fowler et al.,
1976).
Not only are both modalities similar in
their effective mechanisms but hyper-
thermia itself may also enhance the cyto-
toxicity of MISO (Hall et al., 1977; Strat-
ford & Adams, 1977; Bleehen et al.,
1978). However, detailed studies on these
interactions are sparse. In particular, data
on the effect in solid tumours are lacking.
The present experiments were therefore
undertaken to evaluate the relative in-
fluence of the radiosensitizing and cyto-
toxic effects ofMISO andhyperthermiaina
solid tumour and its surrounding tissue, in
order to obtain an optimal therapeutic
effect.
MATERIAL AND MIETHODS
Animal tumour system
Ten-12-week-old male and female C3D2F1/
Bom (C3H/Tify x DBA/2&) mice were used.
The animals were challenged with a spon-
taneously arisen C3H/Tif mammary car-
cinoma, which was propagated by serial
transplantation. Tumour material for inocu-
lum was obtained by sterile dissection of
large flank tumours. Macroscopically viable
tumour tissue was minced with a pair of
scissors, and 5-10 dul of this minced tumour
was injected into the foot on the right hind
limb of the experimental animals. The trans-
plant take was over 9500.
Treatment
Treatment was given to tumours with a
volume of ' 200 mm3 as determined by the
formula D1 x D2x D3x T/6 where the Ds
represent 3 orthogonal diameters. This treat-
ment size was normally obtained about 14
days after inoculation. All treatments were
given to unanaesthetized animals which were
placed in a lucite jig with the tumour-
bearing leg loosely fixed with tape without
impairing the blood flow to the foot (Fig. 1).
Hyperthermia. Local hyperthermia was
administered with the tumour-bearing leg
immersed in a circulating water bath (Heto
type TE 623 or T 643) stabilized to + 0-02°C
of the adjusted temperature. The water bath
was covered with a lucite plate with holes
allowing immersion into the water of the
tumour-bearing leg. Previous measurements
of intratumoural temperature have shown
stabilization within a few minutes to approxi-
mately 0 2°C below the water-bath tempera-
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FIG. 1. Lucite jig for radiation and/or hyperthermic treatment. The unanaesthetized mouse is placed
in the jig and the tumour-bearing leg is loosely taped to the plate, allowing immersion in the
water bath.
ture (Overgaard & Suit, 1979; Overgaard,
1979b). The temperature of the water bath
was therefore adjusted to 0 2°C above the
desired tumour temperature. All further
temperature references in this paper are to the
intratumoral temperature. Temperature
measurements were calibrated against a
certified precision mercury thermometer. In
all experiments the heating time was 60 min.
For radiation given simultaneously with
hyperthermia the tumours were radiated in
the middle of the 1 h hyperthermic period.
Sequential radiation and hyperthermia was
performed by starting thehyperthermic treat-
ment 4 h after completion ofthe radiation.
Irradiation.-Tumours were treated with
graded single doses of radiation to produce
dose-response data. The treatment was given
with a conventional clinical X-ray machine
with a dose rate of 190 rad/min (factors:
250 kV, 15 mA, 2mm Al filtration, I lmm
Cu HVL). The unanaesthetized animals were
placed in lucite jigs and radiated with the
tumours immersed in a water bath and with
5 cm ofwater between the X-ray source and
the tumour, to secure the homogeneity of
the radiation dose (Fig. 2). The remaining
part of the animals was shielded with 4mm
lead. For radiation given simultaneously with
hyperthermia, the water bath was heated to
a desired temperature. For all other radia-
tions, the water bath had room temperature.
Mi8onidazole.-The drug was obtained
through Roche Ltd, Copenhagen (by courtesy
of Rud Hammer Jensen). It was dissolved in
isotonic saline to a concentration of20 mg/ml.
This solution was injected i.p. into non-
anaesthetized mice 30 min before the start of
the irradiation. For treatments given simul-
taneously with hyperthermia, the drug was
injected 5 min before the hyperthermic treat-
ment, and radiation was then started after an
additional 25 min. In experiments analysing
the cytotoxicity of MISO, the drug was given
either immediately or 4 h after irradiation.
Evaluation of results
The animals were followed up with
intervals of at least one week up to 120 days
after treatment.
The response to treatment was measured as
the radiation dose which would on the
average be expected to control 50% of the
treated tumours (TCD5o) at 120 days. The
response ofthe normal tissue was determined
as the radiation dose required to achieve a
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FIG. 2. Experimental set-up for combined hyperthermia and radiation treatment. The mice are
place(l with the tumour-bearing leg in a water bath and irradiated with a 250kV X-ray machine.
During treatment the body of the mouse is shielded with 4 mm of lea(l (not shown). For simul-
taneous hyperthermia and radiation the water was heated to the desiredl temperature. Otherwise
the radiation was givxen with wvater batlh at room temperature.
full moist desquamation of the irradiated
limb within 30 days in 50%o of the animals
(DD50). The TCD50 and DD50 values were
computed by logit analysis (Suit et al., 1965).
The effect on the radiation response of an
additional treatment was calculated as the
"enhancement ratio" (ER) which is the radia-
tion dose required to obtain a given end-point
(TCD50 or DD5o) with radiation alone relative
to the radiation dose needed to obtain the
same response with combined treatment.
Based on the ERs obtained in a given
treatment schedule, a "therapeutic gain
factor" (TGF) w-as calculated as the ER for
the tumour relative to the ER for the normal
tissue. This therapeutic gain factor was the
ultimate objective of the study.
RESULTS
Effect of misonidazole
Administration of MISO 30 min before
irradiation caused a significant decrease in
the radiation TCD5o (Table I). The effect
depended on the drug dose, yielding ERs
of 1-65 and 2-18 for doses of 0 5 mg/g and
10 mg/g MISO, respectively. Thisenhance-
ment was obtained without altering the
radiosensitivity of the surrounding skin,
and therefore represented a similar im-
provement of the therapeutic effect.
Single doses of MISO up to 1 mg/g after
irradiation did not alter the TCD50 sig-
nificantly. Thus, in the present tumour
MISO in single doses showed hypoxic
radiosensitization without direct cyto-
toxicity against hypoxic cells.
Effect of hyperthermiia
As previously reported, the effect of
hyperthermia depended on the sequence
and interval between radiation and heat
(Overgaard, 1979b). Simultaneous treat-
ment produced the greatest thermal en-
13J. OVERGAARD
TABLE L.-Effect ofmisonidazole on the radiation response ofa C3H mammary carcinoma
Radiation alone
(control)
MISO
30 min before
radiation
MISO
immediately after
radiation
MISO
4 h after radiation
Dose of
MISO
(mg/g)
No. of
mice
248
0.5 43
1.0
0.5
49
42
TCD5o (rad)
5622 (5450-5787)*
3415 (30403820)
2574 (2349-2808)
5564 (5237-5909)
1-0 42 5528 (5037-6066)
0 5 43 5783 (5453-6136)
ERt
1.65 (1-50-1-80)
2-18 (2.03-2.35)
1-01 (0.96-1.06)
1-02 (0-95-1-08)
0.97 (0-92-1-02)
*In brackets 95% confidence limits.
=TCD5o radiation alone
tEnhancement ratio (ER)=TCD50combin atme TCD50 combined treatment'
TABLEII.-Effectofsimultaneous MISO and/orsimultaneoushyperthermiaontheradiation
response in a C3H mammary carcinoma and its surrounding skin
Treatment
A_
Hyper-
thermia
MISO 60 min
(30 min (radiation Tumour response
before during No. of A
radiation) heating) mice TCD50 (rad) ERt
Control 248 5622
(5450-5787)*
- 42 50C 78 2299 2-45
(1913-2750) (2-15-2-83)
0.5 mg/g 42 50C 67 1056
(881-1266)
1-0 mg/g 42-50C 60 924
(716-1192)
43 50C 70 1146
(942-1396)
0.5 mg/g 43-50C 85 487
(283-837)
0.5 mg/g 43-50C 35 1014
t h after heat (758-1264)
and radiation)
1-0 mg/g
5-32 (4.88-5.80)
6-08
(5-19-7-13)
4-91
(4.26-5 64)
11-54
(9-01-14-79)
5-54 (4.51-6-82)
43 50C 71 362 15-55
(278-471) (12-84-18-77)
Skin respons
DD50 (rad)
2664
(2464-2882)
1054
(947-1140)
1009
(841-1210)
978
(743-1287)
493
(431-562)
483
(293-783)
500
(222-1107)
Thera-
peutic
3e gain
- factor4
ER (TGF)
2-52
(2.25-2.83)
2-64
(2.36-2.95)
2-72
(2-21-3-35)
5 40 (4.79-6.09)
5.55
(4.75-6.48)
5-33 (3.65-7.76)
456 5-84
(335-625) (4-75-7-17)
0 97
2-01
2-24
0-91
2-08
1-04
2-66
*In brackets 95% confidence limits.
t Enhancement ratio (ER) = Response dose to radiation
Response dose to combined treatment
TGF= ER tumour ERT skinm
hancement, but to the same degree in both
tumour and normal tissue, and a thera-
peutic gain was therefore doubtful (Table
II). On the other hand, selective tumour
cytotoxicity was expressed if the hyper-
thermia was given 4 h after radiation.
Such treatment reduces the TCD50, but
did not enhance the radiation response in
the surrounding normal tissue (Table
III). A sequential treatmentthusimproved
the therapeutic gain. It is reasonable to
assume that the effect of simultaneous
hyperthermia and radiation treatment is
mainly due to hyperthermic radiosensi-
14
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TABLE III.- Effect of simultaneoUs MISO and/orsequential hyperthermia on the radiation
response in a C3H miammary carcinoma and its surrounding skin
Treatment
A- A
Hyper-
thermia
MISO (4 h for
(30 min 60 min Tumour response
before after No. of A
radiation) radiation) mice TCD50 (rad) ERt
Control 248 5622
(5450-5787)*
42-50C 85 3692 1*52
(2838-4717) (1-31-1-77)
0 5 mg/g 42'50C 78 2598 2 16
(1964-3436) (1.90-2.46)
1o0 mg/g 42 50C 81 2434 2 32
(2045-2895) (2 04-262)
1 0 mg/g 42 50C 34 3674 1-53
(4 h after (2890-4673) (1.37-1.71)
radiation)
43 50C 83 2668 2*12
0.5 mg/g
1.0 mg/g
(2315-3073) (1-97-2-26)
43 50C 78 2255 2*49
(1857-2734) (2-17-2.87)
43-50C 76 1836 3 06
(1588-2122) (2.86-3.28)
* In brackets 95% confidence limits.
.,. p.4;. /,P.- - Response dose to radiation T rnnancemen-u rauio kfin)
ER tumour TGF= ERskin
Skin response
~~~ )-
DD50 (rad)
2664
(2464-2882)
2931
(2631-3266)
2568
(1720-3820)
2525
(2122-3006)
2855
(2458-3315)
2641
(2253-3132)
2493
(1798-3456)
2575
(2240-2935)
ER:
0-91
(0.82-1.01)
1-04
(0-94-1-14)
1*05
(0.93-1.20)
0 93
(0-84-103)
1-01
(0-91-1-12)
1-07
(0.91-1.25)
1-03
(0.92-1-21)
TGF
1 67
2 08
2 20
1*64
2*09
2 33
2*97
-Response dose to combined treatment
tization, whereas the sequential treatment
expresses selective hyperthermic cyto-
toxicity against radioresistant (acidic and
chronic hypoxic) tumour cells.
Effect of simultaneous hyperthermia and
MISO
The interaction between hyperthermia
and MISO was first studied in a treatment
schedule where the modalities were applied
simultaneously (Table II). Such a treat-
ment caused a dramatic increase in the
ER of the radiation response in the tu-
mours, ER of up to about 15. This effect
was considerably more than additive.
The increased ER was due to both the dose
of MISO and the heat treatment with the
latter as the most decisive factor (Fig. 3).
Although an additional treatment with
43.50C for 60 min combined with 1 mg/g
misonidazole caused a decreased TCD50
from 5622 rad to 380 rad, radiation was
2
still required to control the tumours. In
fact, in this relatively heat-resistant
tumour, hyperthermia induced only a
minor reduction in growth delay, and
simultaneous MISO and heat caused no
significant delay in tumour growth when
compared to tumours heated alone (data
not shown).
A simultaneous multimodality treat-
ment also increased the radiation response
in normal tissue. This enhancement was
similar to that after simultaneous heat and
radiation treatment alone, so the addition
of MISO only caused extra enhancement
of the tumour response, which in turn
increased the therapeutic ratio (Tables II
andV).
Effect of sequential multimodality treatment
In order to investigate the relative
importance of hypoxic radiosensitization
and the direct hypoxic cytotoxicity, the
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FIG. 3.-Enhancement ratios (ER) for TCD50
intumours treatedwithsimultaneousMISO,
hyperthermia (60 min) and X rays. Vertical
bars represent 95% confidence limits.
treatment wasgiven in different sequential
treatment schedules.
To evaluate whether the hypoxic radio-
sensitization could be enhanced by the
selective hyperthermic cytotoxicity
against radioresistant tumour cells, MISO
was given simultaneously with (i.e. 30 min
before) radiation and then followed after
4 h by local hyperthermia (Table III).
Such treatment increased the ER (Fig. 4).
Theenhancement wasdependentprimarily
on the heat treatment, whereas an in-
crease in MISO dose from 0 5 to 1.0 mg/g
only caused a slight reduction in TCD50.
The ERs were considerably smaller than
those found when all treatment modalities
were given simultaneously, and did not
exceed values about 3. However, such
treatment did not affect the radiation
response in the normal tissue, so the
enhanced tumour effect represented thera-
peutic gain (Tables III and V).
To investigate whether hyperthermia
was able to enhance the potential MISO
0 T~~
42.5'C
z ; 0 0 0 ;; 5 NO HEAT
z
4 T
zI
0 0.5 1.0 'O/g
DOSE OF MISONIDAZOLE
FIG. 4.-ER for TCD50 in tumours treated
with simultaneous MISO and X-rays fol-
lowed after 4 h with hyperthermia (60
min). The open square indicates the ER of
radiation followed after 4 h by simul-
taneous MISO and 42-5°C (60 min). Vertical
bars represent 95% confidence limits.
cytotoxicity against hypoxic cells, a
hyperthermic treatment of 42 5°C for
60 min was given simultaneously with
1 mg/g MISO 4 h after a graded dose of
radiation. Such a treatment resulted in a
TCD50 of 3674 rad (ER 1.53) as compared
to the TCD50 of 3692 rad (ER 1.52) found
for radiation and hyperthermia alone
given in the same schedule (Table III).
Thus this tumour system shows no ther-
mal enhancement of MISO toxicity which
would influence the radiation response.
Similarly no additional cytotoxic effect
ofMISO wasfoundintumourstreatedwith
simultaneous heat and radiation, since a
simultaneous treatment with 43-5°C for
60 min and radiation followed after 4 h
byMISO (0.5 mg/g) gave almost the same
TABLE IV.-Acute lethality in C3D2F1
mice treated with simultaneous or sequen-
tial MISO and hyperthermia
Dose ofMIS (mg/g)
Hyper-
thermia
(for
60 min)
0 5
Simul- S
taneous*
(%)
42-50C 4/71
(6)
43 5°C 20/105
(19)
1.0
,equen- Simul- Sequen-
tialt taneous tial
(%) (%) (%)
0/78 5/65 2/83
(0) (8) (2)
1/79 26/97 2/78
(1) (27) (3)
* MISO 5 min before hyperthermia.
t MISO 4 h before hyperthermia.
I
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TABLE V.-Therapeutic gainfactors
No
lheat
1-00
1-65
2-18
Hyperthermia (60 min)
42 5°C 43 a5C
A A ,
Simultaneous* Sequentialt Simultaneous Sequential
0.97 1-67 0-91 2-09
2-01 2-08 2-08 2-33
2-24 2-20 2-66 2-97
* Hypertlhermia before, during and after radiation.
t Hyperthermia 4 li after radiation.
ER as when the heat and radiation were
given alone (Table II).
Toxicity
Neither hyperthermia nor MISO, in the
doses used here, caused any acute toxicity
(estimated as lethality effect) when given
as individual treatment. However, the
toxicity of MISO was greatly enhanced by
simultaneous treatment with hyper-
thermia at 43°C for 60 min (Table IV) as
previously observed (Overgaard, 1979a).
The use of F, hybrid C3D2F1 mice
instead of our inbred C3H strain reduced
the cytotoxicity to some extent, probably
because this hybrid strain is more resistant
to thermal stress than C3H mice. The
increased toxicity was only found after
simultaneous treatment, and in schedules
where the application of MISO and heat
was given with a 4 h interval, there was
no increased lethality (Table IV).
Therapeutic ratio
In order to estimate the therapeutic
effect of the different treatment schedules,
a therapeutic gain factor (TGF) was
calculated for each schedule (Table V). The
multimodality treatment generally im-
proved the TGF. This was enhanced with
increasing doses of MISO and/or hyper-
thermia, but was almost independent of
whether hyperthermia was applied simul-
taneously with or sequentially after irra-
diation. This was because, although a
simultaneous treatment considerably in-
creased the ERs in the tumours, such
treatment also caused a marked hyper-
thermic sensitization of the radiation
damage in the normal tissue. In contrast,
in treatment schedules where hyperther-
mia was given sequentially, the tumour
response was selectively enhanced without
any changes in the radiation effect in the
skin. Thus, no treatment schedules ex-
ceeded the TGF of 3.
DISCUSSION
The present investigation demonstrates
thathyperthermia andMISO can influence
the radiation response in an experimental
tumour in vivo. The interaction and treat-
ment response strongly depended on the
sequence and timing of the 3 treatment
modalities.
By far the greatest effect was obtained
by a simultaneous treatment with MISO
and hyperthermia, administered imme-
diately before or during radiation therapy.
Such treatment produced ERs up to 15.
This enhancement was dependent on both
the sensitizer dose and the temperature,
but simultaneous treatment caused in all
schedules an ER greater than the product
ofthe ERs whether MISO orhyperthermia
alone was added to the radiation. This
indicates an interaction between the two
modalities when given simultaneously,
which was only detected in tumours,
whereas the normal tissue was not influ-
enced by the administration of MISO,
and only expressed a thermal radiosensi-
tization similar to that previously des-
cribed for this system (Overgaard, 1979b).
Although ERs of up to 15 were ob-
served for the simultaneous multimodality
treatment, the individual effect of either
simultaneous MISO or hyperthermia was
AIISO
(mg/g)
0 5
1-0
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not different from what has previously
been described in other tumour systems
(Robinson et al., 1974a; Fowler et al.,
1976; Brown, 1977; Denekamp & Fowler,
1978; Overgaard, 1978, 1979b).
The effect of combined hyperthermia
and MISO has previously been studied in
solid tumours alone or in combination
with radiation (Bleehen et al., 1977; 1978;
George et al., 1977; Porschen et al., 1978;
Stone, 1978). With a single exception,
the end-point has been in vitro survival or
growth delay, and only Stone (1978)
has studied the effect of combined hyper-
thermia and MISO on the TCD50 radiation
dose. In this study, on a C3H mammary
carcinoma, the individual enhancement
ratio of MISO (1 mg/g) was 2-51, that of
hyperthermia (43°C for 60 min) 1P73, and
the combined treatment showed 5 03.
Thus increases in ER similar though not
identical to the findings in the present
study were observed. However, Stone
gave the heat treatment immediately after
radiation, which may explain the lower
ER, since a simultaneous heat and radia-
tion treatment appears to be critical to
achieve the maximal hyperthermic radio-
sensitization (Overgaard, 1978, 1979b;
Gillette & Ensley, 1979). Unfortunately,
Stone has not described any hyperther-
mia-induced radiosensitization in the nor-
mal tissue. Consequently a comparison of
his therapeutic effect with those observed
in the present study is difficult.
The mechanism of the marked enhance-
ment induced by simultaneous hyper-
thermia, MISO and radiation treatment is
not known. Data based on in vitro assays
have shown a marked hyperthermic en-
hancement oftheMISO toxicity, especially
towards hypoxic cells (Hall et al., 1977;
Sridhar & Sutherland, 1977; Stratford &
Adams, 1977). This appears, however, not
to be a significant factor in our tumour
system. Further MISO treatment does not
significantly increase the delay in tumour
growth relative to the effect of heat alone.
Since the effect is selective for tumours,
it must be associated to certain conditions
characteristic of solid tumours. In several
cell lines, Hofer has observed that 41°G'
given simultaneously withMISOandradia-
tion-sensitized hypoxic cells with ERs of
about 4-1-4-3 in cell lines where the OER
did not exceed 3 (Hofer et al., 1977; Hofer,
1978). Thus, hypoxic cells became even
more sensitive than oxygenated cells
exposed to radiation alone. A similar
sensitization ofhypoxic cells in the present
tumour may account for some of the ERs
obtained.
However, the effect of simultaneous
radiation and hyperthermia is complex.
Although the thermal enhancement is
about the same in tumours and normal
tissue, the mechanism may be partly
different. In the skin, the TER values
probably represent a hyperthermic radio-
sensitization of oxygenated cells, whereas
the tumour enhancement is a result of
thermal radiosensitization of tumour cells
as well as the direct hyperthermic cyto-
toxicity against acidic and chronic hypoxic
ceP.Iq.
The high radiation enhancement ob-
tained by a simultaneous multi-modal
treatment may be explained by consider-
ing the tumour to be composed of two
different compartments of cells: (a) hy-
poxic cells which are selectively destroyed
or sensitized by a hypoxic radiosensitizing
effect of MISO combined with the hyper-
thermic cytotoxicity (expressed by the
effect shown in Table III) and (b) well
oxygenated cells which are exposed to
hyperthermic radiosensitization (similar
to the thermal enhancement of normal
tissue shown in Table II). These oxygena-
ted cells are not influenced by the effect of
MISO nor the direct hyperthermic cyto-
toxicity.
By assuming independent action on the
two different cell compartments of the
combined treatment, the overall tumour
enhancement will be the product of the
ER for the radiation response of hypoxic
cells and the ER for the radiation response
of well oxygenated cells. Table VI illus-
trates that this assumption is consistent
with our experimental findings. This hypo-
thesis also explains why the ERs are
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TABLE VI.-TheobservedandexpectedERs onahypothesis ofindependent action onhypoxic
and oxygenated cells (see text)
ER in
oXygenate(l
cells (from
Treatment h1eat
_A, sensitizatioii
Heat MIS ofskin,
(60 min) (mg/g) Table II)
42 5°C 0 5 2 52
(2 25-2.83)
42 5 C 1.0 2 52
(2 25-2 83)
43 5CC 0-5 5-40
(4.79-6 09)
435(CC 1.0 5 40
(4 79-6.09)
* ER (oxygenated cells) x ER (h1ypoxic cells).
greater in the tumour than in the sur-
rounding skin, since the latter probably
does not contain a significant proportion
of hypoxic cells, judging from the lack of
radiosensitization withMISO in doses upto
1 mg/g.
When MISO is administrated 30 min
before radiation and followed by hyper-
thermia after 4 h, the ER is increased
over that found by radiation treatment
combined with either modality alone.
Such treatment did not affect the radiation
response in normal tissue, and the in-
creased tumour effect can be explained by
a selective radiosensitization and/or cyto-
toxicity against hypoxic tumour cells.
Hyperthermia administrated after irradia-
tion is known to increase the tumour
response by selectively destroying tumour
cells in an acidic and chronic hypoxic
environment (Overgaard, 1976; 1978;
CGerweck et al., 1979; Suit & Gerweck,
1979). Addition of high-dose MISO to the
irradiation treatment may further increase
the radiation sensitivity in acutely hypoxic
(but not necessarily acidic) tumour cells,
and thereby increase the overall treatment
effect in the tumour. Such treatment pro-
duced a maximal ER of about 3 selec-
tively for the tumour response, and is in
agreement with the hypothesis that almost
all hypoxic tumour cells have been either
selectively destroyed or sensitized. The
lack of a clear dose-response relationship
ER inl
lhypoxic
cells (tumour
data from
Table III)
2 16
(1 90-2.46)
2 32
(2.04-2.62)
2 49
(2.17-2 87)
3 06
(2 86-3-28)
Effect of simultaneous
treatment
Exp ER* Obs ER
5.44 532
(4.62-6.41) (4 88-5 80)
5.85 608
(5 03-6 80) (5.19-7.13)
13 45 11 54
(11.39-15 87) (9 01-14 79)
16-52 15.55
(14-51-18-81) (12-84-18-77)
for both MISO and heat treatment in this
schedule may be explained by an "over-
kill" effect on hypoxic cells; thus a high
proportion of the hypoxic cells is both
sensitizedbyMISOanddestroyedbyhyper-
thermia. Any significant heat enhance-
mentofMISOtoxicityis unlikelyto be seen
in this treatment schedule because the
concentrationofMISO atthetimeofhyper-
thermia may be low, owing to the short
half-life ofthe drug in mice (McNally et al.,
1978) and because no enhancement of
drug toxicity against hypoxic cells was
found in tumours where both MISO and
hyperthermia were administrated simul-
taneously 4 h after irradiation.
The lack of hyperthermic enhancement
ofthe cytotoxic effect ofMISO on hypoxic
cells was surprising, since almost all studies
in cell lines in vitro have shown a marked
heat-dependent increase in this drug-
induced cytotoxicity (Hall et al., 1977;
Sridhar & Sutherland, 1977; Stratford &
Adams, 1977). An explanation of this
couldbethattheMISOtoxicityisexpressed
primarily in the chronic hypoxic areas of
the tumour tissues (which are likely to be
more acidic) since increased acidity may
also enhance the MISO cytotoxicity (Strat-
ford, 1977). However, cells in such areas
are almost completely destroyed even by
a moderate heat treatment (e.g. 42-50C for
60 min) as evidenced by histological
examination of heated tumours (Over-
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gaard & Overgaard, 1972; Overgaard &
Nielsen, 1979; Overgaard, 1979b). Thus
both the cytotoxicity ofhyperthermia and
of MISO attack the same cell population
and the effects may overlap each other and
induce "overkill" of chronic hypoxic cells.
Furthermore, the degree of MISO-induced
cytotoxicity against hypoxic cells is prob-
ably relatively small in this tumour sys-
tem, since the TCD50 dose was not in-
fluenced by a postradiation treatmentwith
MISO alone in single doses up to 1 mg/g.
Clinical implications
Provided that the present data are
representative for the general tumour
response, combined MISO, hyperthermia
and radiation therapy may have great
potentials for improving local tumour
control.
The clinical treatment strategy depends
onwhether ornotselective tumourheating
is possible. Ifthe tumour can be heated to
higher temperatures than the surrounding
normal tissue, it is likely that a simul-
taneous multimodality treatment may
enhance the radiation response in the
tumour and thereby improve the thera-
peutic gain. If both tumour and critical
normal tissue are heated to the same
degree, the optimal treatment schedule
wouldappeartobesimultaneousMISO and
irradiation, followed after several hours by
hyperthermia. Such therapy may selec-
tively enhance the tumour response due to
an increased radiosensitivity and/or selec-
tive cytotoxic destruction ofhypoxic cells,
and therefore in turn improve the thera-
peutic ratio.
The heat doses in this experimental
study are within the range that is clinically
acceptable, whereas the MISO would have
to begiveninsmaller dosesin man (Dische,
1978). The effect seems, however, more
dependent on the hyperthermia than on
the drug dose, and it is likely that the
effect of the multimodality treatment will
also be expressed with MISO doses within
the clinically acceptable range in man.
However, before being introduced into
clinicaltherapy, itought to beinvestigated
whether the hyperthermic enhancement of
acute MISO toxicity in mice (Overgaard,
1979a) also operates in humans.
The combination ofMISO, hyperthermia
and radiation appears so promising that
the potential for such therapy should be
further explored.
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